Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
6.03
-0.38 (-5.85%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.01 - 6.44
52 week 3.10 - 7.84
Open 6.40
Vol / Avg. 1.17M/1.03M
Mkt cap 419.93M
P/E 462.07
Div/yield     -
EPS 0.01
Shares 69.64M
Beta 1.67
Inst. own 89%
May 7, 2015
Q1 2015 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 15, 2015
Progenics Pharmaceuticals Inc at Needham Healthcare Conference
Mar 16, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Release
Mar 16, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Feb 24, 2015
Progenics Pharmaceuticals Inc at RBC Healthcare Conference
Feb 10, 2015
Progenics Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - 9.94%
Operating margin - 7.59%
EBITD margin - 14.85%
Return on average assets -29.33% 3.20%
Return on average equity -37.47% 4.33%
Employees 57 -
CDP Score - -

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company�s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. The Company�s product, Relistor, is a treatment for opioid-induced constipation (OIC). PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters